Work

Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.7000

Authors: Ruben A. Mesa, Jean-Jacques Kiladjian, John V. Catalano, Timothy Devos, Miklos Egyed, Andrzei Hellman, Donal McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason R. Gotlib

Institutions: Mayo Clinic, Mayo Clinic in Arizona, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, Monash University, Universitair Ziekenhuis Leuven, Somogy Megyei Kaposi Mór Oktató Kórház, Gdańsk Medical University, King's College Hospital NHS Foundation Trust, University of Miyazaki, Emory University, Gilead Sciences (United States), Hospital Clínic de Barcelona, Stanford Medicine

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2766949843

Cites:

Cited by: 7

Related to: 10